Transdermal Drug Delivery System - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Publication ID:

PB503243673

Publication Date:

March 20, 2024

Pages:

126

Publisher:

MRRPB5

Countries:

Global [1]

USD 3,950.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Transdermal Drug Delivery System is a medicated adhesive patch that is placed on the skin to deliver a specific dose of medication through the skin and into the bloodstream. Often, this promotes healing to an injured area of the body. An advantage of a transdermal drug delivery route over other types of medication delivery such as oral, topical, intravenous, intramuscular, etc. is that the patch provides a controlled release of the medication into the patient, usually through either a porous membrane covering a reservoir of medication or through body heat melting thin layers of medication embedded in the adhesive.
The global market for Transdermal Drug Delivery System was estimated to be worth US$ 15060 million in 2023 and is forecast to a readjusted size of US$ 36450 million by 2030 with a CAGR of 13.3% during the forecast period 2024-2030
Global Transdermal Drug Delivery System key players include Hisamitsu, Mylan, GSK, Novartis, Teve (Actavis), etc. Global top five manufacturers hold a share over 65%. North America is the largest market, with a share over 40%, followed by Europe and Asia-Pacific, both have a share over 45% percent.
In terms of product, Nitroglycerin is the largest segment, with a share over 25%. And in terms of application, the largest application is OTC, followed by RX.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Transdermal Drug Delivery System, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Transdermal Drug Delivery System by region & country, by Type, and by Application.
The Transdermal Drug Delivery System market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Transdermal Drug Delivery System.
Market Segmentation
By Company
Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum
Laboratoires Genevrier
Segment by Type:
Fentanyl
Nitroglycerin
Estradiol
Nicotine
Other
Segment by Application
OTC
Rx
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Transdermal Drug Delivery System manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Transdermal Drug Delivery System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Transdermal Drug Delivery System in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Market Overview
1.1 Transdermal Drug Delivery System Product Introduction
1.2 Global Transdermal Drug Delivery System Market Size Forecast
1.3 Transdermal Drug Delivery System Market Trends & Drivers
1.3.1 Transdermal Drug Delivery System Industry Trends
1.3.2 Transdermal Drug Delivery System Market Drivers & Opportunity
1.3.3 Transdermal Drug Delivery System Market Challenges
1.3.4 Transdermal Drug Delivery System Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Transdermal Drug Delivery System Players Revenue Ranking (2023)
2.2 Global Transdermal Drug Delivery System Revenue by Company (2019-2024)
2.3 Key Companies Transdermal Drug Delivery System Manufacturing Base Distribution and Headquarters
2.4 Key Companies Transdermal Drug Delivery System Product Offered
2.5 Key Companies Time to Begin Mass Production of Transdermal Drug Delivery System
2.6 Transdermal Drug Delivery System Market Competitive Analysis
2.6.1 Transdermal Drug Delivery System Market Concentration Rate (2019-2024)
2.6.2 Global 5 and 10 Largest Companies by Transdermal Drug Delivery System Revenue in 2023
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Transdermal Drug Delivery System as of 2023)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Fentanyl
3.1.2 Nitroglycerin
3.1.3 Estradiol
3.1.4 Nicotine
3.1.5 Other
3.2 Global Transdermal Drug Delivery System Sales Value by Type
3.2.1 Global Transdermal Drug Delivery System Sales Value by Type (2019 VS 2023 VS 2030)
3.2.2 Global Transdermal Drug Delivery System Sales Value, by Type (2019-2030)
3.2.3 Global Transdermal Drug Delivery System Sales Value, by Type (%) (2019-2030)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 OTC
4.1.2 Rx
4.2 Global Transdermal Drug Delivery System Sales Value by Application
4.2.1 Global Transdermal Drug Delivery System Sales Value by Application (2019 VS 2023 VS 2030)
4.2.2 Global Transdermal Drug Delivery System Sales Value, by Application (2019-2030)
4.2.3 Global Transdermal Drug Delivery System Sales Value, by Application (%) (2019-2030)
5 Segmentation by Region
5.1 Global Transdermal Drug Delivery System Sales Value by Region
5.1.1 Global Transdermal Drug Delivery System Sales Value by Region: 2019 VS 2023 VS 2030
5.1.2 Global Transdermal Drug Delivery System Sales Value by Region (2019-2024)
5.1.3 Global Transdermal Drug Delivery System Sales Value by Region (2025-2030)
5.1.4 Global Transdermal Drug Delivery System Sales Value by Region (%), (2019-2030)
5.2 North America
5.2.1 North America Transdermal Drug Delivery System Sales Value, 2019-2030
5.2.2 North America Transdermal Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.3 Europe
5.3.1 Europe Transdermal Drug Delivery System Sales Value, 2019-2030
5.3.2 Europe Transdermal Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.4 Asia Pacific
5.4.1 Asia Pacific Transdermal Drug Delivery System Sales Value, 2019-2030
5.4.2 Asia Pacific Transdermal Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.5 South America
5.5.1 South America Transdermal Drug Delivery System Sales Value, 2019-2030
5.5.2 South America Transdermal Drug Delivery System Sales Value by Country (%), 2023 VS 2030
5.6 Middle East & Africa
5.6.1 Middle East & Africa Transdermal Drug Delivery System Sales Value, 2019-2030
5.6.2 Middle East & Africa Transdermal Drug Delivery System Sales Value by Country (%), 2023 VS 2030
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Transdermal Drug Delivery System Sales Value Growth Trends, 2019 VS 2023 VS 2030
6.2 Key Countries/Regions Transdermal Drug Delivery System Sales Value
6.3 United States
6.3.1 United States Transdermal Drug Delivery System Sales Value, 2019-2030
6.3.2 United States Transdermal Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.3.3 United States Transdermal Drug Delivery System Sales Value by Application, 2023 VS 2030
6.4 Europe
6.4.1 Europe Transdermal Drug Delivery System Sales Value, 2019-2030
6.4.2 Europe Transdermal Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.4.3 Europe Transdermal Drug Delivery System Sales Value by Application, 2023 VS 2030
6.5 China
6.5.1 China Transdermal Drug Delivery System Sales Value, 2019-2030
6.5.2 China Transdermal Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.5.3 China Transdermal Drug Delivery System Sales Value by Application, 2023 VS 2030
6.6 Japan
6.6.1 Japan Transdermal Drug Delivery System Sales Value, 2019-2030
6.6.2 Japan Transdermal Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.6.3 Japan Transdermal Drug Delivery System Sales Value by Application, 2023 VS 2030
6.7 South Korea
6.7.1 South Korea Transdermal Drug Delivery System Sales Value, 2019-2030
6.7.2 South Korea Transdermal Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.7.3 South Korea Transdermal Drug Delivery System Sales Value by Application, 2023 VS 2030
6.8 Southeast Asia
6.8.1 Southeast Asia Transdermal Drug Delivery System Sales Value, 2019-2030
6.8.2 Southeast Asia Transdermal Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.8.3 Southeast Asia Transdermal Drug Delivery System Sales Value by Application, 2023 VS 2030
6.9 India
6.9.1 India Transdermal Drug Delivery System Sales Value, 2019-2030
6.9.2 India Transdermal Drug Delivery System Sales Value by Type (%), 2023 VS 2030
6.9.3 India Transdermal Drug Delivery System Sales Value by Application, 2023 VS 2030
7 Company Profiles
7.1 Hisamitsu
7.1.1 Hisamitsu Profile
7.1.2 Hisamitsu Main Business
7.1.3 Hisamitsu Transdermal Drug Delivery System Products, Services and Solutions
7.1.4 Hisamitsu Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.1.5 Hisamitsu Recent Developments
7.2 Mylan
7.2.1 Mylan Profile
7.2.2 Mylan Main Business
7.2.3 Mylan Transdermal Drug Delivery System Products, Services and Solutions
7.2.4 Mylan Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.2.5 Mylan Recent Developments
7.3 GSK
7.3.1 GSK Profile
7.3.2 GSK Main Business
7.3.3 GSK Transdermal Drug Delivery System Products, Services and Solutions
7.3.4 GSK Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.3.5 Novartis Recent Developments
7.4 Novartis
7.4.1 Novartis Profile
7.4.2 Novartis Main Business
7.4.3 Novartis Transdermal Drug Delivery System Products, Services and Solutions
7.4.4 Novartis Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.4.5 Novartis Recent Developments
7.5 Teve (Actavis)
7.5.1 Teve (Actavis) Profile
7.5.2 Teve (Actavis) Main Business
7.5.3 Teve (Actavis) Transdermal Drug Delivery System Products, Services and Solutions
7.5.4 Teve (Actavis) Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.5.5 Teve (Actavis) Recent Developments
7.6 Johnson & Johnson
7.6.1 Johnson & Johnson Profile
7.6.2 Johnson & Johnson Main Business
7.6.3 Johnson & Johnson Transdermal Drug Delivery System Products, Services and Solutions
7.6.4 Johnson & Johnson Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.6.5 Johnson & Johnson Recent Developments
7.7 Lohmann
7.7.1 Lohmann Profile
7.7.2 Lohmann Main Business
7.7.3 Lohmann Transdermal Drug Delivery System Products, Services and Solutions
7.7.4 Lohmann Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.7.5 Lohmann Recent Developments
7.8 Teikoku Seiyaku
7.8.1 Teikoku Seiyaku Profile
7.8.2 Teikoku Seiyaku Main Business
7.8.3 Teikoku Seiyaku Transdermal Drug Delivery System Products, Services and Solutions
7.8.4 Teikoku Seiyaku Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.8.5 Teikoku Seiyaku Recent Developments
7.9 Bayer
7.9.1 Bayer Profile
7.9.2 Bayer Main Business
7.9.3 Bayer Transdermal Drug Delivery System Products, Services and Solutions
7.9.4 Bayer Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.9.5 Bayer Recent Developments
7.10 Lingrui
7.10.1 Lingrui Profile
7.10.2 Lingrui Main Business
7.10.3 Lingrui Transdermal Drug Delivery System Products, Services and Solutions
7.10.4 Lingrui Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.10.5 Lingrui Recent Developments
7.11 Sanofi
7.11.1 Sanofi Profile
7.11.2 Sanofi Main Business
7.11.3 Sanofi Transdermal Drug Delivery System Products, Services and Solutions
7.11.4 Sanofi Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.11.5 Sanofi Recent Developments
7.12 Qizheng
7.12.1 Qizheng Profile
7.12.2 Qizheng Main Business
7.12.3 Qizheng Transdermal Drug Delivery System Products, Services and Solutions
7.12.4 Qizheng Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.12.5 Qizheng Recent Developments
7.13 Endo
7.13.1 Endo Profile
7.13.2 Endo Main Business
7.13.3 Endo Transdermal Drug Delivery System Products, Services and Solutions
7.13.4 Endo Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.13.5 Endo Recent Developments
7.14 Huarun 999
7.14.1 Huarun 999 Profile
7.14.2 Huarun 999 Main Business
7.14.3 Huarun 999 Transdermal Drug Delivery System Products, Services and Solutions
7.14.4 Huarun 999 Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.14.5 Huarun 999 Recent Developments
7.15 Haw Par
7.15.1 Haw Par Profile
7.15.2 Haw Par Main Business
7.15.3 Haw Par Transdermal Drug Delivery System Products, Services and Solutions
7.15.4 Haw Par Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.15.5 Haw Par Recent Developments
7.16 Nichiban
7.16.1 Nichiban Profile
7.16.2 Nichiban Main Business
7.16.3 Nichiban Transdermal Drug Delivery System Products, Services and Solutions
7.16.4 Nichiban Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.16.5 Nichiban Recent Developments
7.17 Mentholatum
7.17.1 Mentholatum Profile
7.17.2 Mentholatum Main Business
7.17.3 Mentholatum Transdermal Drug Delivery System Products, Services and Solutions
7.17.4 Mentholatum Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.17.5 Mentholatum Recent Developments
7.18 Laboratoires Genevrier
7.18.1 Laboratoires Genevrier Profile
7.18.2 Laboratoires Genevrier Main Business
7.18.3 Laboratoires Genevrier Transdermal Drug Delivery System Products, Services and Solutions
7.18.4 Laboratoires Genevrier Transdermal Drug Delivery System Revenue (US$ Million) & (2019-2024)
7.18.5 Laboratoires Genevrier Recent Developments
8 Industry Chain Analysis
8.1 Transdermal Drug Delivery System Industrial Chain
8.2 Transdermal Drug Delivery System Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Transdermal Drug Delivery System Sales Model
8.5.2 Sales Channel
8.5.3 Transdermal Drug Delivery System Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.2 Data Source
10.2 Author Details
10.3 Disclaimer

Companies Mentioned:

Hisamitsu
Mylan
GSK
Novartis
Teve (Actavis)
Johnson & Johnson
Lohmann
Teikoku Seiyaku
Bayer
Lingrui
Sanofi
Qizheng
Endo
Huarun 999
Haw Par
Nichiban
Mentholatum
Laboratoires Genevrier

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂